AI-Designed Drug AH-001 Complete U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

AnHorn Medicines Achieves Key Milestone in AI-Discovered Therapeutics; Advances Toward Global Licensing and Phase II Development TAIPEI, Oct. 29, 2025 /PRNewswire/ — AnHorn Medicines, a biotech company leveraging generative AI to design small molecules and protein degraders, today…